The estimated Net Worth of Christopher John Kenney is at least 546 千$ dollars as of 21 January 2022. Dr Kenney owns over 700 units of Xenon Pharmaceuticals Inc stock worth over 27,055$ and over the last 3 years he sold XENE stock worth over 24,507$. In addition, he makes 494,828$ as Chief Medical Officer at Xenon Pharmaceuticals Inc.
Dr has made over 2 trades of the Xenon Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 700 units of XENE stock worth 24,507$ on 24 March 2023.
The largest trade he's ever made was selling 700 units of Xenon Pharmaceuticals Inc stock on 24 March 2023 worth over 24,507$. On average, Dr trades about 233 units every 71 days since 2021. As of 21 January 2022 he still owns at least 700 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Dr Kenney stock trades at the bottom of the page.
Dr. Christopher John Kenney M.D. is the Chief Medical Officer at Xenon Pharmaceuticals Inc.
As the Chief Medical Officer of Xenon Pharmaceuticals Inc, the total compensation of Dr D at Xenon Pharmaceuticals Inc is 494,828$. There are 7 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of 2,612,720$.
Dr D is 50, he's been the Chief Medical Officer of Xenon Pharmaceuticals Inc since . There are 17 older and 5 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
Christopher's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over 12,977,011$ worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth 2,649,316$ . The most active insiders traders include Patrick Machado、Partners L P/Ilbiotechnolog...、Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of 818,878$. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth 64,960$.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: